Title |
Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
|
---|---|
Published in |
BMC Biotechnology, November 2011
|
DOI | 10.1186/1472-6750-11-99 |
Pubmed ID | |
Authors |
Mina Rasouli, Zalinah Ahmad, Abdul Rahman Omar, Zeenathul N Allaudin |
Abstract |
Diabetes mellitus is a complicated disease with a pathophysiology that includes hyperinsulinemia, hyperglycemia and other metabolic impairments leading to many clinical complications. It is necessary to develop appropriate treatments to manage the disease and reduce possible acute and chronic side effects. The advent of gene therapy has generated excitement in the medical world for the possible application of gene therapy in the treatment of diabetes. The glucagon-like peptide-1 (GLP-1) promoter, which is recognised by gut L-cells, is an appealing candidate for gene therapy purposes. The specific properties of L-cells suggest that L-cells and the GLP-1 promoter would be useful for diabetes therapy approaches. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Malaysia | 1 | 3% |
United Kingdom | 1 | 3% |
United States | 1 | 3% |
Brazil | 1 | 3% |
Unknown | 32 | 89% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 22% |
Student > Bachelor | 6 | 17% |
Student > Ph. D. Student | 5 | 14% |
Student > Doctoral Student | 3 | 8% |
Student > Postgraduate | 3 | 8% |
Other | 2 | 6% |
Unknown | 9 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 10 | 28% |
Biochemistry, Genetics and Molecular Biology | 9 | 25% |
Medicine and Dentistry | 6 | 17% |
Unspecified | 1 | 3% |
Engineering | 1 | 3% |
Other | 0 | 0% |
Unknown | 9 | 25% |